Some compounded formulations can tolerate controlled room temperature, up to 77 degrees F (25 degrees C), for a limited window that varies by formulation
N Engl J Med (2015) 373(23):224757
By contrast, peptide GLP-1RA COM patents are built on a different logic: claims that cover the precise peptide sequence and its specific modifications, with limited genus scope because the SAR around peptide modifications is exquisitely position-specific
Saxenda (active ingredient: liraglutide) subcutaneous injection Initial FDA Approval: 2014 (liraglutide approved in 2010) Side Effect Update Date: May 28, 2025 Medication Description: For chronic weight management Updated Side Effects/Safety Information: A new warning section on Severe Gastrointestinal Adverse Reactions. An additional warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting
1 (the Budget Reconciliation Act of 2025) take effect
Albuminuria further serves as a dynamic, individualized biomarker that could inform risk stratification and guide tailored management strategies